Hyper-Eosinophilic Syndrome with Myocarditis after Inactivated SARSCoV- 2 Vaccination - A Case Study

Title:Hyper-Eosinophilic Syndrome with Myocarditis after Inactivated SARSCoV- 2 Vaccination - A Case Study

Volume: 18 Issue: 1

Author(s): Ashutosh Tiwari, Gaurav Karna, Sankha Shubhra Chakrabarti, Prasan Kumar Panda*Upinder Kaur

Affiliation:

• All India Institute of Medical Sciences, Rishikesh, India

Keywords: Adverse drug reaction, covaxin, COVID-19 vaccine, dermatological, eosinophilia, myocarditis.

Abstract:

Introduction: COVID-19 vaccine-induced serious adverse reactions are rare. Hypereosinophilia syndrome with myocarditis has not been reported earlier following BBV152 vaccine administration.

Case Presentation: A young man without any co-morbidities presented with persistent periorbital swelling along with itchy swelling over fingers, resting tachycardia, and exertional breathlessness following the first dose of an inactivated SARS-CoV-2 vaccine (BBV152, COVAXIN). On investigation, the patient had elevated blood eosinophils (maximum 21.5% with an absolute eosinophil count of 2767/mm³) and myocarditis (Lake Louise Criteria). He was successfully treated with steroids and supportive treatment.

Conclusion: This is the first reported case of hyper-eosinophilia syndrome after COVAXIN administration. Prior history of the allergic disease may be a predisposing factor in this case. Hypereosinophilia can present with variable symptoms. In the current case, myocarditis was present with persistent resting tachycardia and dyspnea. Steroid and antiallergic drugs may be successful for the treatment of vaccine-induced hyper-eosinophilia with myocarditis. Increased vigilance is needed for such adverse events.

Cite this article as:

Tiwari Ashutosh, Karna Gaurav, Chakrabarti Shubhra Sankha, Panda Kumar Prasan*, Kaur Upinder, Hyper-Eosinophilic Syndrome with Myocarditis after Inactivated SARSCoV- 2 Vaccination - A Case Study, Current Drug Safety 2023; 18 (1) . https://dx.doi.org/10.2174/1574886317666220509165317